KPTI — Karyopharm Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1503802 ·
Last close
$1.92
Market Cap
$43.51M
52W High
$10.86
52W Low
$1.80
ADV30
1,484,781
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 35,066,000 | 33,721,000 | -26,760,000 | -22,392,000 | 131,417,000 | 90,850,000 | 397,063,000 |
| Dec 2025 | 34,079,000 | 32,595,000 | -17,844,000 | -102,198,000 | 108,416,000 | 60,540,000 | 401,342,000 |
| Sep 2025 | 44,044,000 | 41,931,000 | -15,220,000 | -33,127,000 | 96,232,000 | 37,672,000 | 365,490,000 |
| Jun 2025 | 37,929,000 | 36,878,000 | -24,387,000 | -37,252,000 | 104,879,000 | 38,725,000 | 343,805,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-59,113,000
Investing CF
$31,290,000
Financing CF
$79,850,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.09
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,781,891,000
Inventory
$3,599,000
Receivables
$23,357,000
ST Investments
$0
EBIT TTM
$-147,553,000
Pretax Income TTM
$-194,961,000
Interest Exp TTM
$47,408,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$151,118,000
EBITDA
$-83,981,000
Free Cash Flow
$-24,317,876
Enterprise Value
$371,229,216
Total Cash
$90,850,000
Total Debt
$303,212,000
Shares Out
22,662,943
Trailing EPS
$-16.40
Book Value
$-11.78
ROE
—
ROA
-40.6%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 146,067,000 | -90,707,000 | -196,039,000 | 108,416,000 | 401,342,000 | — | -75,369,000 |
| Dec 2024 | 145,237,000 | -119,443,000 | -76,422,000 | 164,418,000 | 350,435,000 | — | -127,486,000 |
| Dec 2023 | 146,033,000 | -129,540,000 | -143,099,000 | 240,438,000 | 376,644,000 | — | -92,723,000 |
| Dec 2022 | 157,074,000 | -142,202,000 | -165,291,000 | 358,172,000 | 374,828,000 | — | -149,554,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-4.89
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RNXT | RenovoRx, Inc. | $43.22M | $0.96 | — |
| CPHI | CHINA PHARMA HOLDINGS, INC. | $44.98M | $1.11 | — |
| IBO | IMPACT BIOMEDICAL INC. | $46.36M | $0.43 | — |
| MCRB | Seres Therapeutics, Inc. | $46.77M | $4.83 | — |
| VICP | Vicapsys Life Sciences, Inc. | $46.94M | $1.45 | — |
News headlines (Yahoo Finance, 1h cache)
Karyopharm’s XPORT-EC-042 study fails to meet primary endpoint
2026-07-31 11:02 · Yahoo
Why Is KPTI Stock Down 69% After-Hours Today?
2026-07-30 22:27 · Yahoo
Karyopharm Plans to Submit sNDA for Selinexor Plus Ruxolitinib in Myelofibrosis Under Accelerated Approval Pathway
2026-07-30 20:06 · Yahoo
Karyopharm Announces Topline Results from Phase 3 XPORT-EC-042 Trial in Endometrial Cancer
2026-07-30 20:05 · Yahoo
Madrigal (MDGL) Reports Q2 Loss, Beats Revenue Estimates
2026-07-30 12:35 · Yahoo
Karyopharm Therapeutics (KPTI) Soars 5.3%: Is Further Upside Left in the Stock?
2026-07-22 11:40 · Yahoo
Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-07-01 20:05 · Yahoo
Karyopharm Therapeutics (KPTI) Stock Sees Split Analyst Revisions After Phase 3 Trial Update
2026-06-25 12:06 · Yahoo
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
2026-06-14 13:57 · Yahoo
Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor (NEXPOVIO®) Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress
2026-06-14 10:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.